Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Adult T-cell leukemia (ATL) is an aggressive hematologic malignancy of poor prognosis caused by human T-cell leukemia virus type 1 (HTLV-1), and it is imperative to develop therapeutic drugs for chemotherapy against ATL. As arsenite or proteasome inhibitor bortezomib induce cell death in HTLV-1-infected T-cells, antitumor effect on ATL can be expected by using these drugs. In this study, we identified that ubiquitin-specific protease 10 (USP10) confers drug resistance phenotype to HTLV-1-infected T-cells. Based on this result, we are currently attempting to identify cellular defense mechanism against drug treatment that USP10 is involved.
|